Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Merck Increases Stock Repurchase Program by $5 Billion

Don't Miss Out —
Follow us on:
Merck Announces New $5 Billion Share Repurchase Program
Vehicles enter the campus of Merck headquarters in Whitehouse Station, New Jersey. Photographer: Emile Wamsteker/Bloomberg

April 27 (Bloomberg) -- Merck & Co., the second-largest U.S. drugmaker, increased a share repurchase program by $5 billion, raising the total amount of stock that can be bought back to $6.4 billion.

Merck, based in Whitehouse Station, New Jersey, announced the new buyback program in a statement today. The drugmaker drew $10.8 billion in cash from operating activities last year, according to a regulatory filing. The company, which pays a quarterly dividend of 38 cents a share, earlier this month agreed to split sales for the arthritis drug Remicade with Johnson & Johnson, ending a dispute that helped drive Merck’s stock down over the last year.

“We do find it encouraging,” Les Funtleyder, a fund manager and health strategist with Miller Tabak & Co. in New York, which holds Merck shares, said of the repurchase program in an e-mail today. “Now that Merck has resolved its case with J&J, it probably feels it has the visibility to deploy its capital.”

Merck rose 57 cents, or 1.6 percent, to $35.63 at 4 p.m. in New York Stock Exchange composite trading. The shares are down 1.1 percent this year.

Also today, Merck won a U.S. panel’s backing to sell its experimental hepatitis C drug. The medicine, boceprevir, is effective and safe enough to support approval, outside advisers to the Food and Drug Administration said today in an 18-0 vote in Silver Spring, Maryland.

To contact the reporter on this story: Meg Tirrell in New York at mtirrell@bloomberg.net.

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.